Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(43)
•••
Comment by Bawkeron May 08, 2019 10:24am
52 Views
Post# 29724175

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Something tells me Kly is a buy at 0.04

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Something tells me Kly is a buy at 0.04
brentkosta wrote:
tysndd wrote: How do you know if I own the stock or what price I bought at why does that kind of personal information mean so much to you ? You come a chat board for a stock you don’t even own and are trying to give out “pro tips” and are trying to get into peoples personal information by assuming how much stock at what price they own it at. Your a loser buddy you have 150 ignores maybe it’s time to get a new profile on here and start over 


Why are you so angry? I dont know what you own... but judging by your childish outbursts, I'd assume you are getting the shyt kicked out of you on this stock. Bummer. I hate to see that. 

I have already made a disclaimer that I DO OWN THIS STOCK. Not much, but some. Why cant I talk about my displeasure with it? Why cant I post on a message board? Why do I need your permission? 

Why do you care so much about me and my followers? Ignore me please. Youre realy embarassing yourself with this emotional outbursts. 

You have every opportunity to block me or log off. Pro-tip: Stop getting so wrapped up in nonsense, It'll drive you mental. I hate to see you struggle like this. 



This is why stockhouse sucks. Clowns like this 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities